A Phase 2 interventional study of Unfocused extracoporeal shock wave therapy in Osteoporosis, sponsored by UMC Utrecht. Completed. Open to female participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-10-12.
Sponsored by UMC Utrecht · Phase 2, Interventional, and Treatment
Rationale: Osteoporotic fractures are associated with high morbidity and mortality. This is why prevention of these fractures is important. The investigators have shown in animal studies that a single treatment with unfocused extracorporeal shock wave therapy leads to highly increased bone mass and improved biomechanical properties. Unfocused extracorporeal shock wave therapy could have important implications for the prevention of osteoporotic fractures.
Objective: To assess the effect of unfocused extracorporeal shock wave therapy on bone mass.
Study design: A clinical pilot study. Study population: Twelve female patients are eligible if they are undergoing elective surgery of the lower extremity or elective spinal surgery under general anesthesia in the investigators hospital.
Intervention: When the patient is under general anaesthesia he/she will receive 3000 unfocused extracorporeal shock waves (energy flux density 0.3mJ/mm2) to one distal forearm. The contra lateral forearm will not be treated and serves as a control.
Main study parameters/endpoints:
The investigators will examine the effect on bone mass with the use of repeated dual energy X-ray absorptiometry measurements. These results are necessary to calculate the number of patients that are needed for larger studies. Furthermore, the investigators will assess patient's discomfort.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: General anaesthesia is performed during treatment and pain after the procedure will be evaluated using pain scales and, if necessary pain medication will be prescribed by the orthopaedic surgeon. The dual energy X-ray absorptiometry-scans and X-rays will cause very low radiation exposure to the patient.
1,640 studies on the registry are indexed under Osteoporosis; 212 are open to participants now.
This study's enrollment of 12 is below the median of 95 across 1,133 interventional studies indexed under Osteoporosis.
Browse Osteoporosis studies →UMC Utrecht is the lead sponsor of 350 studies on the registry; 80 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Unfocused extracorporeal shock wave therapy will be applied on the distal radius on one site when the patient is receiving general anaesthesia for surgery on the lower extremity or spine.
Device: Unfocused extracoporeal shock wave therapy
The distal radius and/or wrist that did not receive UESWT will not be treated
Shock waves are acoustical pulses that are characterized by high amplitude (\~500 bar) and short rise time (\~20 ns), which are followed by a longer low-magnitude negative wave (\~-100 bar). Extracorporeal shock waves are widely used to disintegrate kidney stones, which is called lithotripsy. In orthopedics, shock wave therapy, called orthotripsy, is used safely in a variety of musculoskeletal disorders like non unions, osteonecrosis of the hip, Achilles and patellar tendinopathy, lateral epicondylitis of the elbow and fasciitis plantaris. Until recently extracorporeal shock wave therapy for musculoskeletal disorders was applied with a focused character, in which the waves converge in a focal point similar to lithotripsy. For the prevention of fractures in osteoporosis a focused character is not preferable because large skeletal regions have to be treated, so unfocused shock waves have been developed.
Also known as: Extracorporeal shock waves, Extracorporeal shock wave therapy
Bone mineral density will be assessed with the use of repeated dual energy X-ray absorptiometry measurements
Time frame: 12 weeks
Bone mineral density will be assessed with the use of repeated dual energy X-ray
Time frame: 6 weeks
Pain on the VAS scale
Time frame: day before and first week after treatment
Patient's side effects and complications on a questionnaire
Time frame: 12 weeks
No study locations are listed for this record.
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
UMC Utrecht